Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR0723)
Drug Name
Fluphenazine enanthate
Synonyms
Eutimox; Fluphenazine O-enantate; Fluphenazine enantate; Moditen enanthate; Moditen-retard; Prolixin Enanthate; QSB34YF0W9; SQ 16,114; fluphenazine enanthate; 2-(4-(3-(2-(Trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl heptanoate; 2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethyl heptanoate; 2746-81-8; 4-(3-(2-Trifluoromethyl-10-phenothiazinyl)propyl)-1-piperazineethanol enanthate; BRN 0598595; CCRIS 4033; CHEBI:5125; EINECS 220-385-0; UNII-QSB34YF0W9
Indication Schizophrenia [ICD11: 6A20] Approved [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 549.7 Topological Polar Surface Area 61.3
Heavy Atom Count 38 Rotatable Bond Count 13
Hydrogen Bond Donor Count 0 Hydrogen Bond Acceptor Count 9
Cross-matching ID
PubChem CID
3389
ChEBI ID
CHEBI:5125
CAS Number
2746-81-8
TTD Drug ID
D0P5SA
Formula
C29H38F3N3O2S
Canonical SMILES
CCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F
InChI
1S/C29H38F3N3O2S/c1-2-3-4-5-11-28(36)37-21-20-34-18-16-33(17-19-34)14-8-15-35-24-9-6-7-10-26(24)38-27-13-12-23(22-25(27)35)29(30,31)32/h6-7,9-10,12-13,22H,2-5,8,11,14-21H2,1H3
InChIKey
LRWSFOSWNAQHHW-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Fluphenazine sulfoxide DM004681
3036919
Oxidation - S-oxidation 1 [3]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR005031 Fluphenazine enanthate Fluphenazine sulfoxide Oxidation - S-oxidation CYP2D6 [3]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 2D6 (CYP2D6) DME0009 Homo sapiens
CP2D6_HUMAN
1.14.14.1
[2]
References
1 Fluphenazine Enanthate was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
2 Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos. 1999 Sep;27(9):1078-84.
3 Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol. 1992 Dec 1;44(11):2089-98.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.